The stock of Prime Medicine Inc (NASDAQ: PRME) has increased by 10.53 when compared to last closing price of 2.47.Despite this, the company has seen a gain of 10.98% in its stock price over the last five trading days. globenewswire.com reported 2025-06-18 that MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is undertaking a rights offering (the “Rights Offering”). The Company will be offering a maximum of 353,409,888 rights (the “Rights”) to holders (the “Shareholders”) of its common shares (the “Shares”) as at the close of business on the record date of June 25, 2025 (the “Record Date”) on the basis of one (1) Right for each one (1) Share held. Each one (1) Right will entitle the holder to subscribe for one Share (each, a “Rights Share”) at the subscription price of $0.0825 per Rights Share.
Is It Worth Investing in Prime Medicine Inc (NASDAQ: PRME) Right Now?
The 36-month beta value for PRME is at 2.34. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for PRME is 51.66M, and currently, shorts hold a 35.77% of that float. The average trading volume for PRME on July 02, 2025 was 2.41M shares.
PRME’s Market Performance
PRME’s stock has seen a 10.98% increase for the week, with a 131.36% rise in the past month and a 37.19% gain in the past quarter. The volatility ratio for the week is 16.58%, and the volatility levels for the past 30 days are at 13.72% for Prime Medicine Inc The simple moving average for the past 20 days is 44.96% for PRME’s stock, with a 4.01% simple moving average for the past 200 days.
Analysts’ Opinion of PRME
Many brokerage firms have already submitted their reports for PRME stocks, with Citigroup repeating the rating for PRME by listing it as a “Neutral.” The predicted price for PRME in the upcoming period, according to Citigroup is $1.50 based on the research report published on May 27, 2025 of the current year 2025.
PRME Trading at 69.88% from the 50-Day Moving Average
After a stumble in the market that brought PRME to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.56% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRME starting from Liu David R., who purchase 21,000 shares at the price of $2.52 back on Jun 30 ’25. After this action, Liu David R. now owns 20,240,945 shares of Prime Medicine Inc, valued at $52,830 using the latest closing price.
Liu David R., the 10% Owner of Prime Medicine Inc, purchase 21,000 shares at $2.16 during a trade that took place back on Jun 23 ’25, which means that Liu David R. is holding 20,219,945 shares at $45,402 based on the most recent closing price.
Stock Fundamentals for PRME
Current profitability levels for the company are sitting at:
- -4.96 for the present operating margin
- 0.96 for the gross margin
The net margin for Prime Medicine Inc stands at -4.85. The total capital return value is set at -0.7. Equity return is now at value -115.21, with -63.17 for asset returns.
Based on Prime Medicine Inc (PRME), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86.
Currently, EBITDA for the company is -196.34 million with net debt to EBITDA at -0.15. When we switch over and look at the enterprise to sales, we see a ratio of 9.32. The receivables turnover for the company is 2448.24for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.78.
Conclusion
In conclusion, Prime Medicine Inc (PRME) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
